Charles River Laboratories International, Inc. (NYSE:CRL) Given Consensus Rating of “Moderate Buy” by Brokerages

Charles River Laboratories International, Inc. (NYSE:CRL) has earned a consensus rating of “Moderate Buy” from the sixteen ratings firms that are currently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, four have assigned a hold recommendation and eleven have given a buy recommendation to the company. The average 12 month price target among analysts that have issued ratings on the stock in the last year is $208.50.

CRL has been the topic of a number of recent research reports. CLSA upgraded Charles River Laboratories International from a “hold” rating to an “outperform” rating and raised their target price for the company from $167.00 to $219.00 in a report on Friday. TD Cowen dropped their target price on Charles River Laboratories International from $251.00 to $235.00 and set a “buy” rating on the stock in a report on Friday, February 20th. Robert W. Baird set a $213.00 target price on Charles River Laboratories International in a report on Friday, May 8th. Weiss Ratings upgraded Charles River Laboratories International from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday. Finally, Barclays raised their target price on Charles River Laboratories International from $210.00 to $220.00 and gave the company an “overweight” rating in a report on Friday, May 8th.

Charles River Laboratories International Trading Up 0.8%

Shares of Charles River Laboratories International stock opened at $182.11 on Thursday. The company has a debt-to-equity ratio of 0.90, a quick ratio of 1.03 and a current ratio of 1.36. Charles River Laboratories International has a 52 week low of $132.58 and a 52 week high of $228.88. The stock has a 50 day moving average price of $169.66 and a two-hundred day moving average price of $181.34. The stock has a market capitalization of $8.77 billion, a PE ratio of -48.43, a price-to-earnings-growth ratio of 2.07 and a beta of 1.46.

Charles River Laboratories International (NYSE:CRL) last announced its quarterly earnings data on Thursday, May 7th. The medical research company reported $2.06 EPS for the quarter, beating analysts’ consensus estimates of $1.96 by $0.10. Charles River Laboratories International had a positive return on equity of 15.36% and a negative net margin of 4.59%.The firm had revenue of $995.83 million during the quarter, compared to analysts’ expectations of $977.46 million. During the same quarter last year, the firm posted $2.34 earnings per share. The company’s revenue for the quarter was up 1.2% compared to the same quarter last year. Charles River Laboratories International has set its FY 2026 guidance at 10.800-11.300 EPS. As a group, equities analysts anticipate that Charles River Laboratories International will post 11.04 earnings per share for the current fiscal year.

Institutional Trading of Charles River Laboratories International

A number of hedge funds have recently bought and sold shares of the business. Avidity Partners Management LP bought a new stake in Charles River Laboratories International during the first quarter worth $1,670,000. Glenmede Trust Co. NA lifted its holdings in Charles River Laboratories International by 2.8% during the first quarter. Glenmede Trust Co. NA now owns 2,706 shares of the medical research company’s stock worth $467,000 after acquiring an additional 73 shares during the period. NewEdge Advisors LLC lifted its holdings in Charles River Laboratories International by 707.6% during the first quarter. NewEdge Advisors LLC now owns 2,116 shares of the medical research company’s stock worth $365,000 after acquiring an additional 1,854 shares during the period. Bank of America Corp DE lifted its holdings in Charles River Laboratories International by 5.0% during the first quarter. Bank of America Corp DE now owns 1,135,027 shares of the medical research company’s stock worth $195,792,000 after acquiring an additional 54,500 shares during the period. Finally, Edgestream Partners L.P. bought a new stake in Charles River Laboratories International during the first quarter worth $1,559,000. 98.91% of the stock is currently owned by institutional investors.

About Charles River Laboratories International

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.